We are live on
!
Find out more
VIA
Virtus Investment Advisers Portfolio holdings
AUM
$363M
1-Year Est. Return
34.89%
This Fund
S&P 500
This Quarter
Est. Return
+9.26%
1 Year Est. Return
+34.89%
3 Year Est. Return
+131.43%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$296M
AUM Growth
-$72M
(-20%)
Cap. Flow
-$84.2M
Cap. Flow
% of AUM
-28.48%
Top 10 Holdings %
Top 10 Hldgs %
6.88%
Holding
509
New
39
Increased
197
Reduced
202
Closed
70
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Constellation Energy
CEG
|
+$1.64M |
| 2 |
Veeva Systems
VEEV
|
+$1.51M |
| 3 |
Cisco
CSCO
|
+$1.5M |
| 4 |
Fox Class A
FOXA
|
+$1.48M |
| 5 |
DoorDash
DASH
|
+$1.48M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Virtus Newfleet ABS/MBS ETF
VABS
|
+$32.2M |
| 2 |
Virtus Newfleet Short Duration High Yield Bond ETF
VSHY
|
+$24.6M |
| 3 |
Virtus SEIX Senior Loan ETF
SEIX
|
+$19M |
| 4 |
SMC
Summit Midstream
SMC
|
+$3.67M |
| 5 |
State Street SPDR Bloomberg High Yield Bond ETF
JNK
|
+$2.09M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Financials | 33.24% |
| 2 | Healthcare | 17.43% |
| 3 | Technology | 12.41% |
| 4 | Industrials | 9.1% |
| 5 | Consumer Discretionary | 4.73% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
MAZE
401
Maze Therapeutics
MAZE
$1.59B
| $85.2K | 0.03% |
+6,940
| New | +$72.2K |
|
402
Biohaven
BHVN
$2.21B
| $85.1K | 0.03% |
6,032
+1,949
| +48% | +$34.7K |
|
403
Janux Therapeutics
JANX
$967M
| $85K | 0.03% |
3,679
+1,011
| +38% | +$26.6K |
|
404
Wave Life Sciences
WVE
$1.2B
| $84.9K | 0.03% |
13,060
+1,210
| +10% | +$7.99K |
|
405
Revolution Medicines
RVMD
$44B
| $84.1K | 0.03% |
2,287
-1,365
| -37% | -$52.4K |
|
406
Crinetics Pharmaceuticals
CRNX
$8.92B
| $84.1K | 0.03% |
2,923
-30
| -1% | -$926 |
|
407
Viridian Therapeutics
VRDN
$2.67B
| $83.9K | 0.03% |
6,001
-3,128
| -34% | -$42.5K |
|
|
DFTX
408
Definium Therapeutics
DFTX
$6.12B
| $83.6K | 0.03% |
12,881
-10,507
| -45% | -$69.1K |
|
409
Annexon
ANNX
$886M
| $83.3K | 0.03% |
34,698
-1,701
| -5% | -$3.41K |
|
|
TECX
410
Tectonic Therapeutic
TECX
$606M
| $83.3K | 0.03% |
4,190
+649
| +18% | +$13.2K |
|
|
RNAM
411
DELISTED
Avidity Biosciences
RNAM
| $83.1K | 0.03% |
2,926
-1,934
| -40% | -$57.6K |
|
412
Syndax Pharmaceuticals
SNDX
$1.82B
| $82.5K | 0.03% |
8,813
-3,379
| -28% | -$37.2K |
|
413
Immatics
IMTX
$1.32B
| $82.4K | 0.03% |
15,315
-6,838
| -31% | -$33.9K |
|
414
uniQure
QURE
$3.22B
| $82K | 0.03% |
5,881
-5,025
| -46% | -$67.6K |
|
415
Taysha Gene Therapies
TSHA
$1.89B
| $82K | 0.03% |
35,484
-37,473
| -51% | -$81.4K |
|
416
Arcus Biosciences
RCUS
$3.64B
| $81.9K | 0.03% |
10,057
+485
| +5% | +$4.14K |
|
417
Kura Oncology
KURA
$850M
| $81.5K | 0.03% |
14,119
-2,823
| -17% | -$17.3K |
|
|
KALV
418
DELISTED
KalVista Pharmaceuticals
KALV
| $81.2K | 0.03% |
+7,184
| New | +$87.8K |
|
419
Arbutus Biopharma
ABUS
$915M
| $81.2K | 0.03% |
26,266
-19,848
| -43% | -$65.9K |
|
420
Liquidia Corp
LQDA
$8.02B
| $81.1K | 0.03% |
6,507
-8,403
| -56% | -$124K |
|
421
NewAmsterdam Pharma
NAMS
$3.34B
| $81K | 0.03% |
4,471
-2,072
| -32% | -$37.8K |
|
422
Entrada Therapeutics
TRDA
$267M
| $80.5K | 0.03% |
11,979
+2,914
| +32% | +$23.4K |
|
423
Edgewise Therapeutics
EWTX
$4.73B
| $79.9K | 0.03% |
6,098
+269
| +5% | +$3.88K |
|
424
Spyre Therapeutics
SYRE
$9.25B
| $79.5K | 0.03% |
5,310
-1,551
| -23% | -$22.9K |
|
425
Cullinan Oncology
CGEM
$1.14B
| $79.1K | 0.03% |
10,506
-2,949
| -22% | -$23.7K |
|
Similar funds
RC
MS
WI
HS
SIAG
WTFG
A6
ACM
Virtus Investment Advisers's Q2 2025 Portfolio in Review
As of Q2 2025, Virtus Investment Advisers held 509 positions worth $296M, down 20% from $368M the previous quarter. Its ten largest holdings account for 6.9% of the portfolio.
Virtus Investment Advisers withdrew a net $84.2M in Q2 2025, closing 70 positions and reducing 202 holdings. Its most notable exit was Virtus Newfleet ABS/MBS ETF, an estimated $32.2M position sold in full.
By sector, the portfolio is most concentrated in Financials at 33% of assets, up from 24% a quarter earlier, followed by Healthcare and Technology.
Against the trend, Virtus Investment Advisers opened a new position in Constellation Energy worth $2.01M.
- Virtus Investment Advisers's largest Q2 2025 buy was Constellation Energy: 6,213 shares worth $2.01M.
- Virtus Investment Advisers added most to Amgen in Q2 2025, an estimated $1.45M increase.
- Virtus Investment Advisers's biggest Q2 2025 reduction was EOG Resources, cutting an estimated $1.23M.
- Virtus Investment Advisers fully exited Virtus Newfleet ABS/MBS ETF in Q2 2025, selling an estimated $32.2M.
- Virtus Investment Advisers's ten largest holdings make up 6.9% of its $296M portfolio in Q2 2025.
- Virtus Investment Advisers opened 39 new positions and closed 70 in Q2 2025.
- Virtus Investment Advisers's portfolio value fell 20% quarter-over-quarter to $296M.
Based on Virtus Investment Advisers's 13F filing for Q2 2025, filed 13 Aug 2025.